More than 1.7 million treatments of Sanofis ArteSunate AmodiaQuine Winthrop® (ASAQ Winthrop, fixed dose artemisinin-based combination therapy), manufactured with semisynthetic artesunate in Morocco, are being shipped from Sanofis distribution center to Burkina Faso, Burundi, Democratic Republic of the Congo, Liberia, Niger, and Nigeria over the next few months. This shipment represents a critical step in improving access to effective treatments and combatting malaria in some of the most affected countries in the world, said Dr. Robert Sebbag, vice president of Sanofis Access to Medicines. Sanofi is proud that these first batches of antimalarial medicines produced with semisynthetic artemisinin derivative are on the way to reaching patients. This milestone is the result of the enduring partnership between PATH and Sanofi that has translated years of effort into lifesaving change. Both artesunate (the active ingredient produced from semisynthetic artemisinin) and semisynthetic artemisinin have been shown to be identical to those derived from botanical sources. Consequently, there are no changes to the quality of ASAQ Winthrop®.
Posted on: Tue, 12 Aug 2014 14:31:35 +0000
Trending Topics
Recently Viewed Topics
© 2015